Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(100.0%)
1Total
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03335605Completed

Improving the Diagnosis of Common Variable Immune Deficiency

Role: collaborator

NCT05321407Active Not Recruiting

COVID-19 Vaccine Responses in PIDD Subjects

Role: collaborator

NCT03968211Phase 1Completed

Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

Role: collaborator

All 3 trials loaded